Abstract 302P
Background
DNA repair pathways are implicated both in carcinogenesis and progression of cancer. The genetically determined baseline expression level of DNA repair genes is associated with risk of cervical pre-cancer and cancer. In this study, we aim to evaluate expression level of one such DNA repair gene -Excision Repair Cross- Complementation Group 4 (ERCC4) and its correlation to various clinical and pathological parameters in cervical cancer in North Indian population.
Methods
Expression profiling of ERCC4 in 55 histopathologically confirmed cervical tumor biopsies and 25 control samples (hysterectomy) were done using Real time PCR(q-PCR), western blot analysis. Correlation analysis was done with different clinical and pathological parameters. ROC curve assessment was done to check the diagnostic utilities of the calculated data. One way ANOVA and t-test were used to calculate statistical significance using Graphpad PRISM 9.
Results
Relative fold change for mRNA expression analysis showed up-regulation of ERCC4 in 78.2% (n=43) patient biopsies, calculated by ΔΔct method. At translational level, the up regulation was around 52% (n=28). The up-regulations were significant with p value less than 0.05. Also, ERCC4, mRNA expression showed positive correlation with tumor stage and grade. Positive correlation was also observed in ERCC4 protein expression with respect to different age groups and histological status. High risk HPV-18 strain type was shown to be more influential in up regulating ERCC4 expression, both at transcriptional and translational level.
Conclusions
ERCC4 is significantly up-regulated at both transcriptional and translational levels in cervical cancer patient cohort, comprising of North Indian population. Higher expression of ERCC4 in tumor samples suggests its role as a potential diagnostic and/or prognostic marker in Ca Cervix.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute of Medical Sciences, BHU, Varanasi, India.
Funding
BHU under Institute of Eminence (IoE).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract